RobertJeffreySilverMD
Endocrinology • Brooklyn, NYDiabetes, Lipid Metabolism, Thyroid
Assistant Professor of Clinical Medicine, Weill Cornell Medicine, New York N.Y. Chief, Division of Endocrinology, New York Presbyterian-Brooklyn Methodist Hospital, Brooklyn N.Y.
Overview of Dr. Silver
Dr. Robert Silver is an endocrinologist in Brooklyn, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian Brooklyn Methodist Hospital. He received his medical degree from Rutgers New Jersey Medical School and has been in practice 18 years. Dr. Silver accepts several types of health insurance, listed below. He is one of 23 doctors at NewYork-Presbyterian Brooklyn Methodist Hospital and one of 142 doctors at New York-Presbyterian Hospital who specialize in Endocrinology.
Office
506 6th St
Brooklyn, NY 11215Fax+1 718-780-3259
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2005
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1999 - 2002
Rutgers New Jersey Medical SchoolClass of 1999
Certifications & Licensure
NY State Medical License 2022 - 2026
NH State Medical License 2005 - 2025
MA State Medical License 2003 - 2006
PA State Medical License 2000 - 2002- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Diabetes Recognition Program National Committee for Quality Assurance, 2012-2015
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Fellow (FACE) American Association of Clinical Endocrinology
- Join now to see all
Clinical Trials
- Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease Start of enrollment: 2013 Mar 18
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) Start of enrollment: 2014 Feb 01
- A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes Start of enrollment: 2014 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 170 citationsEfficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trialOfri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, Jan W. Eriksson, Simon Heller
The Lancet. Diabetes & Endocrinology. 2019-07-01 - 63 citationsSwitching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized...Harpreet S. Bajaj, Richard M. Bergenstal, Andreas Christoffersen, Melanie J. Davies, Amoolya Gowda
Diabetes Care. 2021-07-01 - 222 citationsUse of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 DiabetesAllison B. Goldfine, Robert J. Silver, Waleed Aldhahi, Dongsheng Cai, Elizabeth Tatro
Clinical and Translational Science. 2008-05-01
Press Mentions
Cannabis Exposure Linked to 1.5 Times Higher Risk of Unhealthy Pregnancy OutcomesDecember 14th, 2023- Using Weed During Pregnancy May Raise Risk of Child Having Autism or ADHD by 30%, Large Review Warns – Is This Partly Why Rates of Both Conditions Are Rising in US?March 12th, 2024
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPOGreat West PPO
Harvard Pilgrim HMO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Tufts Health Plan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
